China clears first CAR-T for solid tumors, 9 years after blood cancer

China's drug regulator approved Satri-cel (CT041), the world's first CAR-T cell therapy for solid tumors, extending cell therapy beyond the blood cancers where it has been available since 2017.

"Satri-cel opens a new treatment option for patients with solid tumors who have had limited choices after standard therapies fail," a representative at Jiahui International Cancer Center, which will offer the therapy to patients globally, said.

The therapy, developed by CARsgen Therapeutics (2171.HK), targets Claudin18.2, a protein expressed in gastric, pancreatic and other gastrointestinal cancers. CARsgen's pipeline includes multiple candidates targeting solid tumor antigens, with Satri-cel being the first to reach regulatory approval.

The approval sets a regulatory precedent that could accelerate similar programs at larger drugmakers pursuing solid tumor CAR-T therapies. The solid tumor patient population is several times larger than blood cancers, representing a potential multibillion-dollar market expansion for cell therapy.

How Satri-cel Differs From Existing CAR-T Therapies

All six approved CAR-T therapies globally target blood cancers such as lymphoma, leukemia and multiple myeloma. Satri-cel is the first to target a solid tumor antigen, overcoming challenges including the tumor microenvironment that has historically limited CAR-T efficacy in solid tumors. CARsgen's CT041 has been studied across multiple clinical trials, with data presented at oncology conferences showing responses in gastric cancer patients who had failed prior lines of therapy.

The mechanism of action is similar to blood cancer CAR-Ts: a patient's T cells are extracted, genetically engineered to recognize cancer cells, and reinfused. But solid tumors present additional barriers — a dense extracellular matrix, immunosuppressive cells and limited tumor penetration — that have made them resistant to earlier CAR-T approaches. Satri-cel's targeting of Claudin18.2, a protein highly expressed in certain gastrointestinal cancers but largely absent from healthy tissue, helps overcome some of these challenges.

Competitive Field

CARsgen is not alone in pursuing solid tumor CAR-T. Bristol Myers Squibb and Johnson & Johnson, which already market blood cancer CAR-T therapies, have early-stage programs targeting solid tumors. Arcellx, a private biotech, is developing a next-generation CAR-T platform aimed at solid tumors. Moderna has also entered the space, bringing an in vivo CAR-T approach that uses mRNA to program immune cells inside the body rather than extracting and engineering them externally.

The Chinese biotech sector has become a significant player in cell therapy, with multiple companies developing CAR-T candidates for both blood and solid tumors. China's NMPA has been more willing than the FDA or EMA to approve first-in-class cell therapies, having previously approved the first anti-PD-1 antibody from a domestic developer.

Market Implications

The global CAR-T market has grown rapidly since the first approval in 2017, with therapies from Novartis, Gilead Sciences, Bristol Myers Squibb and Johnson & Johnson generating billions in combined annual sales. Solid tumors represent the next growth frontier, and this approval could spur increased investment and competition in the space.

CARsgen, with cash reserves reported in its most recent financial filing, is positioned to scale manufacturing and pursue additional indications for Satri-cel. The company may also seek approval in other markets, though regulatory pathways outside China remain unclear.

This article is for informational purposes only and does not constitute investment advice.